| Nontraditional analgesics for the management of postherpetic neuralgia. | |
| | |
MedLine Citation:
|
PMID: 3987215 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
The pathogenesis and clinical manifestations of herpes zoster and postherpetic neuralgia and the use of nontraditional analgesics in the management of postherpetic neuralgia are reviewed. Herpes zoster represents the reactivation in an immunocompromised host of dormant varicella-zoster virus (Herpesvirus varicellae) contracted during a previous episode of chickenpox. Fever, neuralgia, and paresthesia occur four to five days before skin lesions develop. Acute herpes zoster pain usually does not last more than two weeks after all skin lesions have healed. Postherpetic neuralgia is defined as pain that persists in the affected dermatomes after the disappearance of all skin crusts. The neuralgia can vary from "lightninglike" stabbing pain to constant, burning pain with hyperesthesia; it can persist for years and is often refractory to traditional analgesic therapy. A number of nontraditional analgesic agents have been used in the management of postherpetic neuralgia. Tricyclic antidepressants, especially amitriptyline, have been used alone and in combination with phenothiazines or anticonvulsants (carbamazepine, phenytoin, valproate sodium), with good results. The effectiveness of phenothiazines or anticonvulsants as sole therapeutic agents has not been demonstrated. Although the intralesional administration of corticosteroids appears to be beneficial, considerable fear about the potential for these agents to precipitate widespread viral dissemination exists. Positive results have been reported with levodopa, amantadine, and interferon, but the role of these agents in the prevention of postherpetic neuralgia remains unclear. Nontraditional analgesic agents are useful in the management of postherpetic neuralgia, but patients must be selected and monitored appropriately. A tricyclic antidepressant (especially amitriptyline) is a reasonable first choice. |
| | |
Authors:
|
M Thompson; M Bones |
Related Documents
:
|
8027505 - Clinical effects of organophosphorus cholinesterase inhibitors. 9667165 - A randomized clinical trial of agents to reduce sensitivity after crown cementation. 16776595 - Neurotrophins: mediators and modulators of pain. 7504575 - Clinical considerations in the use of risperidone. 7658235 - Clinical efficacy of spect bone imaging for low back pain. 15077255 - Structural, psychological, and genetic influences on low back and neck pain: a study of... |
Publication Detail:
|
Type: Journal Article |
Journal Detail:
|
Title: Clinical pharmacy Volume: 4 ISSN: 0278-2677 ISO Abbreviation: Clin Pharm Publication Date: 1985 Mar-Apr |
Date Detail:
|
Created Date: 1985-06-07 Completed Date: 1985-06-07 Revised Date: 2004-11-17 |
Medline Journal Info:
|
Nlm Unique ID: 8207437 Medline TA: Clin Pharm Country: UNITED STATES |
Other Details:
|
Languages: eng Pagination: 170-6 Citation Subset: IM |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Adrenal Cortex Hormones
/
therapeutic use Adult Aged Analgesics* Anticonvulsants / therapeutic use Antidepressive Agents, Tricyclic / therapeutic use Herpes Zoster / complications, diagnosis, drug therapy* Humans Methylprednisolone / therapeutic use Middle Aged Neuralgia / diagnosis, drug therapy*, etiology Phenothiazines / therapeutic use Triamcinolone / therapeutic use |
| Chemical | |
Reg. No./Substance:
|
0/Adrenal Cortex Hormones; 0/Analgesics; 0/Anticonvulsants; 0/Antidepressive Agents, Tricyclic; 0/Phenothiazines; 124-94-7/Triamcinolone; 83-43-2/Methylprednisolone |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Management of maldigestion associated with pancreatic insufficiency.
Next Document: Pharmacokinetics of ceftriaxone in subjects with renal insufficiency.